ReviewInternational journal of general medicine2026
Recent Advances in Pathogenesis, Diagnosis and Integrated Traditional Chinese Medicine Therapy for Plasma Cell Mastitis.
Review in International journal of general medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plasma cell mastitis (PCM) is a predominant form of non-lactational mastitis with an increasing incidence worldwide. The condition is characterized by a complex pathogenesis, difficulties in differential diagnosis, and a high rate of recurrence, thereby presenting significant challenges in clinical management. Conventional Western medicine is limited by high postoperative recurrence, difficulty in distinguishing PCM from breast cancer, and unsatisfactory long-term efficacy of single anti-inflammatory or hormone therapy. Against these clinical bottlenecks, Traditional Chinese medicine (TCM) shows unique advantages and accumulated extensive clinical experience for the treatment of PCM. This review systematically delineates the epidemiological characteristics and key pathophysiological mechanisms, including activation of the IL-6/STAT3 signaling pathway, immune cell dysregulation, autoimmune responses, distinctive plasma cell infiltration, and diagnostic methodologies such as imaging techniques, histopathological examination as the diagnostic gold standard, and emerging biomarkers. In addition, the theoretical foundations, contemporary pharmacological mechanisms, and clinical applications of comprehensive TCM therapy for PCM are summarized. Evidence indicates that TCM interventions, guided by syndrome differentiation and targeting liver qi stagnation, phlegm-stasis congealing, and heat-toxin accumulation, exert therapeutic effects by modulating inflammatory signaling pathways, correcting immune dysfunction, and restoring the mammary gland microecological balance. Clinical trials have demonstrated that combining TCM with surgical procedures or western medical treatments significantly improves clinical outcomes, reduces inflammatory mediator levels, and lowers recurrence rates. However, there remains a need for standardization in TCM syndrome differentiation, therapeutic evaluation criteria, and high-quality randomized controlled trials. In summary, integrated TCM therapy constitutes a safe and effective approach for managing PCM, and further rigorous research is warranted to enhance its clinical application and facilitate international recognition of TCM in PCM treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.